| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.35 | 2e-11 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-10 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-10 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.24 | 4e-10 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-10 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | 0.23 | 7e-10 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-08 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-07 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-06 |